Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.41 |
| ▸ | NPY4R | P50391 | 5/20 | 0.41 |
| ▸ | NPY1R | P25929 | 4/20 | 0.41 |
| ▸ | NPY2R | P49146 | 2/20 | 0.41 |
| ▸ | FURIN | P09958 | 2/20 | 0.41 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22336348 | 0.97 | TRPV1 (0.44) | TRPV1NPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL22336351 | 0.97 | TRPV1 (0.44) | TRPV1NPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL21754508 | 0.93 | NPY4R (0.47) | TRPV1NPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL25826708 | 0.93 | NPY4R (0.47) | TRPV1NPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL24496678 | 0.91 | TRPV1 (0.42) | TRPV1NPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL23815045 | 0.91 | CHRND (0.44) | TRPV1NPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL22746602 | 0.90 | TRPV1 (0.42) | TRPV1NPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL24496495 | 0.90 | TRPV1 (0.45) | TRPV1NPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL27432789 | 0.89 | NPY4R (0.44) | TRPV1NPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL27432923 | 0.89 | NPY4R (0.44) | TRPV1NPY5RNPY4RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210355230-A1 | USE OF ANTI-CD5 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2021-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355230-A1 | USE OF ANTI-CD5 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY | CD59, CD58, CD2 | TRPV1 2565/4885NPY5R 2455/4885NPY4R 3682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.